Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Phase of Trial: Phase III
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Ablynx
- 24 Aug 2017 According to an Ablynx media release, more than 80% of eligible HERCULES patients having rolled over into this follow-up study.
- 12 Oct 2016 Accoroding to an Ablynx media release, the first patient has rolled-over into this trial from HERCULES study.
- 12 Oct 2016 Accoroding to an Ablynx media release, status changed from not yet recruiting to recruiting.